Increased hemoglobin levels above baseline by 1.4 to 2.0 g/dL in most subjects, with some showing intra-subject hemoglobin increase of 1.5 to 4.3 g/dL, exceeding the threshold set for the primary ...

Increased hemoglobin levels above baseline by 1.4 to 2.0 g/dL in most subjects, with some showing intra-subject hemoglobin increase of 1.5 to 4.3 g/dL, exceeding the threshold set for the primary ...

Increased hemoglobin levels above baseline by 1.4 to 2.0 g/dL in most subjects, with some showing intra-subject hemoglobin increase of 1.5 to 4.3 g/dL, ... Ruxoprubart provides complete control over ...

3 McKinley CE, Richards SJ, Munir T, et al. Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome. Blood. 2017;130(Supplement 1 ...

The disease is currently treated with C5 inhibitors, but these fail to address extravascular hemolysis, a key issue in PNH management. Zaltenibart is an investigational MASP-3 inhibitor, ...

SEATTLE, March 21, 2025--Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart ...

Omeros (OMER) reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in paroxysmal nocturnal hemoglobinuria. Zaltenibart ...

3 McKinley CE, Richards SJ, Munir T, et al. Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome. Blood. 2017;130(Supplement 1 ...

Adding intra-arterial urokinase or tenecteplase didn’t significantly increase the likelihood of surviving without disability at 90 days in the POST-UK and POST-TNK trials, respectively, although the ...

Iptacopan, a first-in-class oral factor B inhibitor, acts upstream of C5, inhibiting both terminal complement–mediated intravascular hemolysis and complement 3–mediated extravascular hemolysis ...

Voydeya (danicopan tablets) has been approved in Canada as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have residual ...

Principal support for the approval came from the randomized phase III ALPHA trial, which evaluated standard treatment with or without danicopan in 73 patients with PNH and significant ...